BRPI1013938A2 - "peptídeos ttk e vacinas incluindo os mesmos" - Google Patents
"peptídeos ttk e vacinas incluindo os mesmos"Info
- Publication number
- BRPI1013938A2 BRPI1013938A2 BRPI1013938A BRPI1013938A BRPI1013938A2 BR PI1013938 A2 BRPI1013938 A2 BR PI1013938A2 BR PI1013938 A BRPI1013938 A BR PI1013938A BR PI1013938 A BRPI1013938 A BR PI1013938A BR PI1013938 A2 BRPI1013938 A2 BR PI1013938A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccines including
- ttk
- peptides
- ttk peptides
- vaccines
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21601709P | 2009-05-11 | 2009-05-11 | |
PCT/JP2010/003166 WO2010131452A1 (en) | 2009-05-11 | 2010-05-10 | Ttk peptides and vaccines including the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1013938A2 true BRPI1013938A2 (pt) | 2019-09-24 |
Family
ID=43084837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1013938A BRPI1013938A2 (pt) | 2009-05-11 | 2010-05-10 | "peptídeos ttk e vacinas incluindo os mesmos" |
Country Status (13)
Country | Link |
---|---|
US (1) | US8530430B2 (pt) |
EP (1) | EP2430039A4 (pt) |
JP (1) | JP5786178B2 (pt) |
KR (1) | KR20120029394A (pt) |
CN (1) | CN102459314B (pt) |
AU (1) | AU2010248702A1 (pt) |
BR (1) | BRPI1013938A2 (pt) |
CA (1) | CA2761393A1 (pt) |
MX (1) | MX2011012013A (pt) |
RU (1) | RU2531348C2 (pt) |
SG (1) | SG175998A1 (pt) |
TW (1) | TW201102081A (pt) |
WO (1) | WO2010131452A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2895600T3 (da) | 2012-09-11 | 2020-04-27 | Onco Therapy Science Inc | Ube2t-peptider og vacciner, der indeholder disse |
WO2018090257A1 (zh) * | 2016-11-16 | 2018-05-24 | 深圳华大基因研究院 | 多肽及其应用 |
CN109952308B (zh) * | 2016-11-29 | 2022-09-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
SG11202000250PA (en) * | 2017-07-12 | 2020-02-27 | Nouscom Ag | A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers |
WO2024077601A1 (en) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Peptide vaccines against glioma and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187548B1 (en) * | 1993-05-23 | 2001-02-13 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Methods using human calcium sensor protein, fragments thereof and DNA encoding same |
US20030045491A1 (en) | 2001-02-23 | 2003-03-06 | Christoph Reinhard | TTK in diagnosis and as a therapeutic target in cancer |
KR100876327B1 (ko) | 2001-02-21 | 2008-12-31 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 진단에서의, 그리고 암에서 치료 표적으로서의 ttk |
US7501243B2 (en) * | 2001-02-21 | 2009-03-10 | Novartis Vaccines And Diagnostics, Inc. | Detection of colon or breast cancer by measuring TTK polypeptide expression |
JP2005527180A (ja) | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス, インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
US7428517B2 (en) * | 2002-02-27 | 2008-09-23 | Brands Michael Rik Frans | Data integration and knowledge management solution |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
PT1581812E (pt) | 2003-01-06 | 2008-09-22 | Wyeth Corp | Composições e métodos para diagnóstico e tratamento de cancros do cólon |
WO2004070062A2 (en) | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
CA2539651A1 (en) | 2003-09-22 | 2005-04-07 | Rosetta Inpharmatics Llc | Synthetic lethal screen using rna interference |
WO2005073374A1 (ja) * | 2004-01-29 | 2005-08-11 | Dainippon Sumitomo Pharma Co., Ltd. | 新規腫瘍抗原蛋白質及びその利用 |
GB0426393D0 (en) | 2004-12-01 | 2005-01-05 | Cancer Rec Tech Ltd | Materials and methods relating to modulators of spindle checkpoint kinases |
CN102605067A (zh) | 2004-12-08 | 2012-07-25 | 安万特药物公司 | 测量对多西他赛抗药性或敏感性的方法 |
CN101175862A (zh) | 2005-02-10 | 2008-05-07 | 肿瘤疗法科学股份有限公司 | 诊断膀胱癌的方法 |
ES2364670T3 (es) * | 2005-02-25 | 2011-09-12 | Oncotherapy Science, Inc. | Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk. |
JP5150909B2 (ja) | 2005-07-27 | 2013-02-27 | オンコセラピー・サイエンス株式会社 | 食道癌を診断する方法 |
JP2009502115A (ja) | 2005-07-27 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | 小細胞肺癌の診断方法 |
JP2010512730A (ja) | 2006-12-13 | 2010-04-30 | オンコセラピー・サイエンス株式会社 | 肺癌の腫瘍マーカーおよび治療標的としてのttk |
TWI610939B (zh) | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
CA2708686A1 (en) | 2007-12-21 | 2009-07-02 | University Health Network | Methods of inhibiting tumor growth using ttk antagonists |
TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2010
- 2010-05-05 TW TW099114328A patent/TW201102081A/zh unknown
- 2010-05-10 SG SG2011082963A patent/SG175998A1/en unknown
- 2010-05-10 AU AU2010248702A patent/AU2010248702A1/en not_active Abandoned
- 2010-05-10 MX MX2011012013A patent/MX2011012013A/es active IP Right Grant
- 2010-05-10 WO PCT/JP2010/003166 patent/WO2010131452A1/en active Application Filing
- 2010-05-10 CA CA2761393A patent/CA2761393A1/en not_active Abandoned
- 2010-05-10 BR BRPI1013938A patent/BRPI1013938A2/pt not_active IP Right Cessation
- 2010-05-10 KR KR1020117027534A patent/KR20120029394A/ko not_active Application Discontinuation
- 2010-05-10 CN CN201080031259.2A patent/CN102459314B/zh not_active Expired - Fee Related
- 2010-05-10 US US13/320,022 patent/US8530430B2/en not_active Expired - Fee Related
- 2010-05-10 JP JP2011548451A patent/JP5786178B2/ja not_active Expired - Fee Related
- 2010-05-10 EP EP10774711A patent/EP2430039A4/en not_active Withdrawn
- 2010-05-10 RU RU2011150283/04A patent/RU2531348C2/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2011150283A (ru) | 2013-06-20 |
EP2430039A1 (en) | 2012-03-21 |
US8530430B2 (en) | 2013-09-10 |
AU2010248702A1 (en) | 2011-11-17 |
CA2761393A1 (en) | 2010-11-18 |
MX2011012013A (es) | 2012-02-23 |
US20120135020A1 (en) | 2012-05-31 |
CN102459314A (zh) | 2012-05-16 |
EP2430039A4 (en) | 2012-12-05 |
SG175998A1 (en) | 2011-12-29 |
JP2012526519A (ja) | 2012-11-01 |
KR20120029394A (ko) | 2012-03-26 |
WO2010131452A1 (en) | 2010-11-18 |
TW201102081A (en) | 2011-01-16 |
RU2531348C2 (ru) | 2014-10-20 |
CN102459314B (zh) | 2016-01-20 |
JP5786178B2 (ja) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201500177B (it) | Combinazione terapeutica comprendente dolutegravir, abacavir e lamivudina | |
BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
BR112012013148A2 (pt) | formulação farmacêutica e uso | |
BR112012004546A2 (pt) | "terapêutica por proteínas ligantes dll4-ligantes" | |
HK1200489A1 (en) | Recombinant human naglu protein and uses thereof naglu | |
DK2552434T3 (da) | Peptider og anvendelse deraf | |
BRPI0908936A2 (pt) | vacinas de flavivírus de replicação defeituosa e vetores de vacina | |
BRPI0807544A2 (pt) | Sólido farmacêutico e dose de vacina | |
DK3572091T3 (da) | Modificerede relaxinpolypeptider og anvendelser deraf | |
BR112012006501A2 (pt) | polipeptídios e usos dos mesmos | |
BRPI0914782A2 (pt) | peptídeos de epítopos de cdca1 e vacinas contendo os mesmos | |
BRPI1008887A2 (pt) | peptídeos de foxm1 e vacinas contendo os mesmo | |
BR112012003844A2 (pt) | vacinas de pttv e diagnóstico | |
NL301214I2 (nl) | Lasmiditan en farmaceutisch aanvaardbare zouten daarvan | |
BR112012004731A2 (pt) | peptídeos derivados de wnt10 e uso dos mesmos | |
BRPI1009301A2 (pt) | peptídeos neil 3 e vacinas incluindo os mesmos | |
BRPI1013938A2 (pt) | "peptídeos ttk e vacinas incluindo os mesmos" | |
BRPI0916940A2 (pt) | peptídeos de epítopo de melk e vacinas contendo os mesmos. | |
BRPI1012312A2 (pt) | peptídeos vangl1 e vacinas incluindo os mesmos | |
BR112013013158A2 (pt) | peptídeos de tomm34 e vacinas incluindo os mesmos | |
BRPI1010666A2 (pt) | peptídeos de cdc45l e vacinas incluindo dos mesmos | |
BRPI0923402A2 (pt) | Peptídeos c10rf59 e vacinas incluindo os mesmos. | |
BR112013013551A2 (pt) | composto e uso médico do mesmo | |
BRPI1013384A2 (pt) | peptídeos c6orf167 e vacinas incluindo os mesmos | |
IL220146A0 (en) | Tmem22 peptides and vaccines including the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |